{"commentary":{"count":230,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":111,"youtube":68,"podcast":46,"x_video":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04700124\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"KEYNOTE-B15","nct_id":"NCT04700124","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-b15-nct04700124. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"KEYNOTE-B15","arms":[{"description":"Participants receive 4 cycles (each cycle length = 21 days) of EV intravenous (IV) infusion plus pembrolizumab IV infusion preoperatively, followed by RC + PLND, followed by 5 cycles of adjuvant EV IV infusion plus 13 cycles of adjuvant pembrolizumab IV infusion postoperatively. The total treatment duration is up to approximately 1 year.","label":"Arm A: Perioperative EV+ Pembrolizumab and RC + PLND","type":"EXPERIMENTAL"},{"description":"Participants receive 4 cycles (each cycle length = 21 days) of standard of care (SOC) chemotherapy (gemcitabine IV infusion plus cisplatin IV infusion) preoperatively, followed by RC + PLND. The total treatment duration is up to approximately 3 months.","label":"Arm B: Standard of Care (SOC)-Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND","type":"ACTIVE_COMPARATOR"}],"collaborators":["Seagen Inc.","Astellas Pharma Inc"],"completion_date":{"date":"2028-05-18","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":808,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Enfortumab vedotin (EV)","type":"BIOLOGICAL"},{"name":"RC + PLND","type":"PROCEDURE"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-07-16","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-10-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-Free Survival (EFS)","timeFrame":"Up to ~68 months"}],"references":[{"citation":"Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Alvarez-Fernandez C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gomez de Liano A; KEYNOTE-B15/EV-304 Investigators. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23;395(4):338-348. doi: 10.1056/NEJMoa2601486.","pmid":"42485627","type":"DERIVED"}],"start_date":{"date":"2021-04-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","url":"https://clinicaltrials.gov/study/NCT04700124"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-b15-nct04700124"}